Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 26;55(5):1033–1048. doi: 10.3892/ijo.2019.4886

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Ferreira et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

CEA is expressed in patients with NSCLC. (A) Western blot analysis of CEA glycoprotein in tumour lysates. Protein (20 µg) obtained from NSCLC patients' tissues were ran in reduced SDS-PAGE gels and blotted with anti-CEA mAb. The numbers above each lane represent the patient number. The lane N corresponds to a representative normal tissue lysate from a patient with NSCLC (patient number 7), showing negative anti-CEA reactivity. This figure shows a blot with tracks from samples analysed separately. (B) sLe^x/sLe^a and E-selectin ligands expression in CEA-negative and CEA-positive patients. The tumour/normal ratios of sLe^x/sLe^a expression (left) and E-selectin ligands expression (right) were calculated and separated for CEA-negative and CEA-positive patients. Box-and-whisker plots represent median values, and upper and lower quartiles (boxes), ranges and all values for each group (black dots). ^*P<0.05. (C) sLe^x/sLe^a, E-selectin ligands and CEA have overlapping staining profiles in NSCLC tissues. Sequential paraffin-embedded NSCLC tissue sections from patients 2, 7, 10 and 15 were stained with HECA-452 mAb (left), E-Ig chimera (middle), and anti-CEA mAb (right) via immunohistochemistry. Nuclei were stained with haematoxylin. Magnification, ×10. CEA, carcinoembryonic antigen; E-Ig, mouse E-selectin-human Fc Ig chimera; E-SL, E-selectin; mAb, monoclonal antibody; N, normal; NSCLC, non-small cell lung cancer; sLe^a/x, sialyl Lewis a/x.

CEA is expressed in patients with NSCLC. (A) Western blot analysis of CEA glycoprotein in tumour lysates. Protein (20 µg) obtained from NSCLC patients' tissues were ran in reduced SDS-PAGE gels and blotted with anti-CEA mAb. The numbers above each lane represent the patient number. The lane N corresponds to a representative normal tissue lysate from a patient with NSCLC (patient number 7), showing negative anti-CEA reactivity. This figure shows a blot with tracks from samples analysed separately. (B) sLe^x/sLe^a and E-selectin ligands expression in CEA-negative and CEA-positive patients. The tumour/normal ratios of sLe^x/sLe^a expression (left) and E-selectin ligands expression (right) were calculated and separated for CEA-negative and CEA-positive patients. Box-and-whisker plots represent median values, and upper and lower quartiles (boxes), ranges and all values for each group (black dots). ^*P<0.05. (C) sLe^x/sLe^a, E-selectin ligands and CEA have overlapping staining profiles in NSCLC tissues. Sequential paraffin-embedded NSCLC tissue sections from patients 2, 7, 10 and 15 were stained with HECA-452 mAb (left), E-Ig chimera (middle), and anti-CEA mAb (right) via immunohistochemistry. Nuclei were stained with haematoxylin. Magnification, ×10. CEA, carcinoembryonic antigen; E-Ig, mouse E-selectin-human Fc Ig chimera; E-SL, E-selectin; mAb, monoclonal antibody; N, normal; NSCLC, non-small cell lung cancer; sLe^a/x, sialyl Lewis a/x.